FDA-authorized profile

Caption Guidance

Bay Labs, Inc. · Ultrasound · FDA-authorized (De Novo)

Ultrasound guidance software that helps users capture standard adult heart ultrasound clips.

Clinical role
Real-time acquisition guidance using Quality Meter feedback, Prescriptive Guidance for probe maneuvers, Auto-Capture of predicted diagnostic-quality clips, and Save Best Clip.
Images and patients
Ultrasound · Heart, including the standard PLAX, PSAX-AV, PSAX-MV, PSAX-PM, AP4, AP5, AP2, AP3, SubC4, and SC-IVC views.
Key limitation
Use is restricted to the listed adult 2D heart ultrasound views and compatible probe; users must inspect the anatomy and image resolution themselves.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?It gives real-time guidance to help a user move an ultrasound probe and capture standard heart ultrasound clips.
  • Which scans and patients is it intended for?It is for standard adult 2D heart ultrasound views on the labeled Terason system and compatible probe.
  • Who uses it?Medical professionals, including trained sonographers and people without specialized echocardiography training, may use it.
  • What does the software produce, and what must the clinician do?It provides image-quality feedback, probe guidance, and saved clips. Qualified professionals must check image quality and make the diagnosis.
  • What is its most important limitation?It is prescription-only and limited to the compatible probe and listed ultrasound exam; it is not for transesophageal exams.

Clinical takeaway. Caption Guidance supports ultrasound image capture rather than interpretation. The clinician remains responsible for adequate images and diagnosis.

Evidence takeaway. The FDA material reports studies of image quality and acquisition endpoints. The reported results are not sensitivity or specificity measures.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Real-time acquisition guidance and image-quality optimization for medical professionals obtaining standard adult 2D-TTE views; the device supports image acquisition, while qualified medical professionals remain responsible for image quality and diagnosis.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Real-time acquisition guidance using Quality Meter feedback, Prescriptive Guidance for probe maneuvers, Auto-Capture of predicted diagnostic-quality clips, and Save Best Clip.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Adult 2D-TTE acquisitions on the labeled Terason uSmart 3200t Plus ultrasound system with the compatible 4V2A linear phased-array probe, covering the ten standard views listed in the FDA indication.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Real-time expected image-quality feedback, probe-maneuver guidance toward standard views, automatic capture of predicted diagnostic-quality clips, and retrospective saving of the highest-quality clip when Auto-Capture is not achieved.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Point-of-care echocardiography, including bedside and clinical settings outside a traditional cardiology department.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Medical professionals, including trained sonographers and professionals without specialized echocardiography training; the evaluated groups included hospitalists, nurse practitioners or physician assistants, registered nurses, medical residents, and certified medical assistants.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Prescription use only. Users remain responsible for image quality and diagnosis, and qualified professionals must inspect data for appropriate anatomy and spatial and temporal resolution. The device is not intended for transesophageal or other unlisted ultrasound exams, must be used only with the compatible Terason 4V2A probe, and requires ultrasound exposure to follow displayed MI/TI values and ALARA principles.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
A prospective specialist study scanned 50 patients with and without guidance and used three expert cardiologists with the ACEP quality scale; 97.85% of auto-captured clips were diagnostic. The pivotal study trained at least eight RNs to acquire 30 patients each with and without guidance and used five expert cardiologists. Four primary scan-level endpoints were satisfied: sufficient quality for LV size, global LV function, RV size, and non-trivial pericardial effusion at 98.8%, 98.8%, 92.5%, and 98.8%, respectively, with stated confidence intervals. Secondary agreement, clip-quality, AutoEF, linear-measurement, and human-factors results are separate workflow or usability endpoints, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
A prospective specialist study scanned 50 patients with and without guidance and used three expert cardiologists with the ACEP quality scale; 97.85% of auto-captured clips were diagnostic. The pivotal study trained at least eight RNs to acquire 30 patients each with and without guidance and used five expert cardiologists. Four primary scan-level endpoints were satisfied: sufficient quality for LV size, global LV function, RV size, and non-trivial pericardial effusion at 98.8%, 98.8%, 92.5%, and 98.8%, respectively, with stated confidence intervals. Secondary agreement, clip-quality, AutoEF, linear-measurement, and human-factors results are separate workflow or usability endpoints, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for DEN190040. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult 2D-TTE acquisitions on the labeled Terason uSmart 3200t Plus ultrasound system with the compatible 4V2A linear phased-array probe, covering the ten standard views listed in the FDA indication.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA DEN190040: Caption Guidance

  2. Routing

    Source context, not route validation: Caption Guidance is installed on the third-party Terason uSmart 3200t Plus system, with access to both the Terason and Caption Guidance user interfaces. The reviewed FDA packet does not establish DICOM, PACS, RIS, or other downstream interface support.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA DEN190040: Caption Guidance

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-09 ·

  4. Returned objects

    Source context, not route validation: Real-time expected image-quality feedback, probe-maneuver guidance toward standard views, automatic capture of predicted diagnostic-quality clips, and retrospective saving of the highest-quality clip when Auto-Capture is not achieved.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA DEN190040: Caption Guidance

  5. Viewer/worklist/report

    Unresolved route: Real-time expected image-quality feedback, probe-maneuver guidance toward standard views, automatic capture of predicted diagnostic-quality clips, and retrospective saving of the highest-quality clip when Auto-Capture is not achieved.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA DEN190040: Caption Guidance

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Caption Guidance is installed on the third-party Terason uSmart 3200t Plus system, with access to both the Terason and Caption Guidance user interfaces. The reviewed FDA packet does not establish DICOM, PACS, RIS, or other downstream interface support.
  • Exact FDA submission
  • Checked 2026-09-09
Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. Identity bridge: Caption Health's own press page states Bay Labs renamed to Caption Health (2019), and GE HealthCare's own press release announces the acquisition of Caption Health, Inc.; Caption AI is sold as a GE HealthCare product. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
The De Novo decision summary states Caption Guidance is designed for use as an assistive tool for trained sonographers as well as medical professionals without specialized echocardiography training, and the special controls require labeling to include a description of the intended user population and the recommended user training.
  • Exact FDA submission
  • Checked 2026-10-27

The summary also documents the training given to users in the pivotal study (didactic and hands-on guided training provided by a Caption Health representative, ending in a user readiness evaluation); that describes the study conduct, not a verified current mandatory training program.

Monitoring
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Caption Guidance; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
DEN190040
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Heart, including the standard PLAX, PSAX-AV, PSAX-MV, PSAX-PM, AP4, AP5, AP2, AP3, SubC4, and SC-IVC views.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
De Novo
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-02-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-authorized
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-09Last searched
17Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda de novo summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact DEN190040 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-09 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA DEN190040: Caption Guidance

    U.S. Food and Drug Administration - Published 2020-02-07 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Caption Guidance model card (DEN190040)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for DEN190040

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. DEN190040 FDA decision

    Regulatory record

    De Novo

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260844

ACUSON Sequoia Diagnostic Ultrasound System;ACUSON Sequoia Select Diagnostic Ultrasound System;ACUSON Origin Diagnostic Ultrasound System;ACUSON Origin ICE Diagnostic Ultrasound System

Siemens Medical Solutions USA, Inc.

Authorized purpose: ACUSON Sequoia, Select, Origin, and Origin ICE diagnostic ultrasound systems acquire and display the labeled fetal, abdominal, pediatric, neonatal, cephalic, small-part, obstetric, cardiac, transesophageal, intracardiac, vascular, and musculoskeletal examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; transesophageal and intracardiac applications
Decision
2026-06-16
FDA-cleared K260300

WatchMate Software

Anumana, Inc.

Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.

Modality
Ultrasound
Anatomy
Heart and left atrial appendage
Decision
2026-06-15
FDA-cleared K260780

HeartFocus

Deski

Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-06-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history